Statements (32)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
|
| gptkbp:administeredBy |
oral
|
| gptkbp:approvalYear |
2005
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01XE05
|
| gptkbp:brand |
gptkb:Nexavar
|
| gptkbp:CASNumber |
284461-73-0
|
| gptkbp:chemicalFormula |
C21H16ClF3N4O3
|
| gptkbp:developedBy |
gptkb:Bayer
gptkb:Onyx_Pharmaceuticals |
| gptkbp:genericName |
gptkb:sorafenib
|
| gptkbp:legalStatus |
prescription only
patented |
| gptkbp:mechanismOfAction |
gptkb:receptor_tyrosine_kinase
|
| gptkbp:molecularWeight |
464.8 g/mol
|
| gptkbp:pregnancyCategory |
D (US)
|
| gptkbp:prescribes |
adults
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
diarrhea
fatigue hypertension rash |
| gptkbp:target |
gptkb:PDGFR
gptkb:VEGFR gptkb:RAF_kinase |
| gptkbp:usedFor |
gptkb:renal_cell_carcinoma
hepatocellular carcinoma differentiated thyroid carcinoma |
| gptkbp:bfsParent |
gptkb:Bayer_HealthCare
gptkb:sorafenib |
| gptkbp:bfsLayer |
6
|
| https://www.w3.org/2000/01/rdf-schema#label |
Nexavar
|